Tibsovo® (ivosidenib) – New orphan drug approval
July 20, 2018 - Agios announced the FDA approval of Tibsovo (ivosidenib), for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.
Top